Delivery Order V797D70102-36C26025F0002

Award Date 10/1/24
Potential Completion Date 9/30/25
Potential Value $163K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bartlett, TN 38134, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder, to the Department of Veterans Affairs (VA). The prime contractor is Vanda Pharmaceuticals Inc., doing business as Vanda, a global biopharmaceutical company. The contract was awarded as a Blanket Purchase Agreement (BPA) call against Vanda's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract, with a potential value of $220,629.46. The contract...
This is a federal contract award to Vanda Pharmaceuticals Inc., a for-profit pharmaceutical manufacturer, by the U.S. Department of Veterans Affairs (VA). The contract, which is not set aside, is a delivery order under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with a ceiling value of $154,048.79 and a performance period through December 31, 2024. Vanda Pharmaceuticals is the sole manufacturer of HETLIOZ (tasimelteon), a specialized medication used to treat...
This federal contract award from the Department of Veterans Affairs (VA) to Vanda Pharmaceuticals Inc. (Vanda) is for the delivery of the medication Hetlioz (tasimelteon) to the VA's Veterans Integrated Service Network 16. The $128,543.49 delivery order contract is a firm fixed-price instrument placed against Vanda's Pharmaceuticals and Drugs GSA Schedule contract. Hetlioz is used to treat Non-24-Hour Sleep-Wake Disorder, a condition affecting many veterans. This award is not designated as a...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Harmony Biosciences LLC, a pharmaceutical company specializing in medications for rare neurological diseases and sleep disorders. The award was for the delivery of WAKIX 17.8 mg tablets, a drug used to treat excessive daytime sleepiness and cataplexy in adult narcolepsy patients. The contract is a Firm Fixed Price Delivery Order under Harmony Biosciences' Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals...
This federal contract award was issued by the Veterans Integrated Service Network 5 (VISN 5) of the U.S. Department of Veterans Affairs (VA) to Harmony Biosciences LLC, a pharmaceutical company specializing in rare neurological diseases and sleep disorders. The $10,170 firm-fixed-price delivery order is for WAKIX 17.8 MG, a medication used to treat excessive daytime sleepiness and cataplexy in adult narcolepsy patients. The contract is issued against Harmony Biosciences' General Services...
This federal contract award is a delivery order valued at $656,342.82 issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Harmony Biosciences LLC, a pharmaceutical company that specializes in developing and manufacturing medications for rare neurological diseases and sleep disorders. The award is for the bulk order of WAKIX (pitolisant) tablets, a medication used to treat excessive daytime sleepiness and cataplexy in adult narcolepsy patients. Harmony...
This is a firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Harmony Biosciences, LLC, a pharmaceutical company that specializes in medications for rare neurological diseases and sleep disorders. The contract is for the supply of WAKIX (pitolisant) 17.8 mg tablets, a treatment for excessive daytime sleepiness and cataplexy in adult narcolepsy patients. The contract was issued against the VA's Pharmaceuticals and Drugs Federal Supply Schedule...
This is a firm fixed-price delivery order issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Harmony Biosciences LLC, a pharmaceutical company that specializes in developing and manufacturing medications to treat rare neurological diseases and sleep disorders. The award is for the supply of WAKIX (pitolisant) tablets, a medication used to treat excessive daytime sleepiness and cataplexy in adult narcolepsy patients. The contract has a ceiling value of...
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Harmony Biosciences LLC, a pharmaceutical company that specializes in developing and manufacturing medications to treat rare neurological diseases and sleep disorders. The contract is a delivery order against Harmony Biosciences' existing General Services Administration (GSA) Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The award is for WAKIX...
This federal contract award is a delivery order issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Harmony Biosciences LLC, a pharmaceutical company that specializes in rare neurological diseases and sleep disorders. The $10,170.00 firm fixed price order is for the drug WAKIX (pitolisant) and is issued against Harmony Biosciences' General Services Administration (GSA) Federal Supply Schedule (FSS-61-IB) Pharmaceuticals and Drugs contract. This award is not...

This federal contract award is for the delivery of HETLIOZ (tasimelteon), a pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to the prime contractor, Vanda Pharmaceuticals Inc., doing business as Vanda, on October 1, 2024. The contract has a ceiling value of $162,771.05 and a performance period extending through September 30, 2025. This award is a delivery order placed against Vanda's existing GSA Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract is not designated as a set-aside. Vanda is the sole manufacturer of HETLIOZ, a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. This contract supports the VA's efforts to provide specialized pharmaceutical products to eligible veterans, addressing their unique medical needs. In addition to this delivery order, Vanda holds a significant Blanket Purchase Agreement (BPA) with the VA National Acquisition Center, further demonstrating the VA's reliance on Vanda as a key supplier of HETLIOZ.

Generated 10/2/24, 11:03 AM